Following a full submission
AWMSG advice |
||
| Status: Recommended | ||
Tipranavir (Aptivus®) is recommended for use within NHS Wales for the treatment of human immunodeficiency virus (HIV-1) infection, only for the treatment of highly pre-treated adult patients who have failed multiple protease inhibitors (PI), and where resistance profiling suggests it is appropriate. Use should be in accordance with the British HIV Association (BHIVA) guidance. |
||
|
||
Medicine details |
||
| Medicine name | tipranavir (Aptivus®) | |
| Formulation | 250 mg capsule | |
| Reference number | 52 | |
| Indication | In combination with low dose ritonavir for combination antiretroviral treatment of HIV infection in highly pre-treated adult patients with virus resistant to multiple protease inhibitors |
|
| Company | Boehringer Ingelheim Ltd | |
| BNF chapter | Infections | |
| Assessment type | Full | |
| Status | Recommended | |
| Advice number | 0707 | |
| NMG meeting date | 12/07/2007 | |
| AWMSG meeting date | 15/08/2007 | |
| Ratification by Welsh Government | 29/08/2007 | |
| Date of issue | 07/09/2007 | |